Hypoxia positron emission tomography imaging with 18F-fluoromisonidazole

被引：235

作者：

Lee, Sze Ting

Scott, Andrew M.

机构：

[1] Austin Hlth, Ctr PET, Melbourne Ctr Clin Sci, Heidelberg, Vic 3084, Australia

[2] Univ Melbourne, Austin Hlth, Dept Med, Heidelberg, Vic, Australia

来源：

SEMINARS IN NUCLEAR MEDICINE | 2007年 / 37卷 / 06期

关键词：

D O I：

10.1053/j.semnuclmed.2007.07.001

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The importance of hypoxia in disease pathogenesis and prognosis is gathering increasing clinical significance and having a greater impact on patient management and outcome. Previous efforts to evaluate hypoxia have included the invasive assessment of hypoxia with immunohistologic and histographic oxygen probes. The emergence of new radiotracers has allowed noninvasive assessment of hypoxia, with the most extensively investigated and validated positron emission tomography radiotracer of hypoxia to date being F-18-fluoromisonodazole (F-18-FMISO). This review discusses the relevance and biology of hypoxia in cells and organ systems, and reviews the laboratory and clinical applications of F-18-FMISO in oncology and noncancer disease states.

引用

页码：451 / 461

页数：11

共 108 条

[11]

CALDWELL JH, 1995, J NUCL MED, V36, P1633

[12] QUANTITATIVE MEASUREMENTS OF OXYGEN TENSION IN NORMAL TISSUES AND IN THE TUMOURS OF PATIENTS BEFORE AND AFTER RADIOTHERAPY [J].